Huntington's disease (HD) is a late onset neurodegenerative disorder caused by a CAG/polyglutamine (polyQ) repeat expansion. PolyQ aggregates can be detected in the nuclei and processes of neurons in HD patients and mouse models prior to the onset of symptoms. The misfolding and aggregation pathway is an important therapeutic target. To better test the efficacy of aggregation inhibitors, we have developed an organotypic slice culture system. We show here that the formation of polyQ aggregates in hippocampal slices established from the R6/2 mouse follows the same prescribed sequence as occurs in vivo. Using this assay, we show that Congo red and chrysamine G can modulate aggregate formation, but show complex dose-response curves. Oral administration of creatine has been shown to delay the onset of all aspects of the phenotype and neuropathology in R6/2 mice. We show here that creatine can similarly inhibit aggregate formation in the slice culture assay.
INTRODUCTION
Huntington's disease (HD) is one of eight neurodegenerative disorders caused by the expansion of a CAG/polyQ repeat. CAG tracts of less than or equal to 35 repeats have not been reported to cause HD, whereas individuals with 40 or more will invariably go on to develop the disease and those in the 36 -39 range show incomplete penetrance (Myers et al., 1998) . Age of onset is generally in midlife while expansions at the higher end of the mutant range result in the juvenile form of the disease. HD symptoms are variable and include psychiatric disturbances, a movement disorder, and cognitive decline. Neuronal cell death occurs primarily in the striatum and cortex, although many other brains regions can be affected (Harper, 1996) . The polyQ aggregate pathology is present in the form of nuclear inclusions and neuropil aggregates which most likely contain an N-terminal fragment of the huntingtin protein (Becher et al., 1998; DiFiglia et al., 1997; Gutekunst et al., 1999) . Aggregates are most prevalent in the cerebral cortex, where they have also been described in the brains of presymptom-
